{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T14:29:06Z","timestamp":1705588146909},"reference-count":18,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2012,4]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>It remains unclear whether a long\u2010acting preparation of octreotide (Sandostatin <jats:styled-content style=\"fixed-case\">LAR<\/jats:styled-content>) can be safely used for portal hypertension in patients with compensated cirrhosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>To determine the safety and efficacy of <jats:styled-content style=\"fixed-case\">LAR<\/jats:styled-content> among patients with Child Pugh Class A or B cirrhosis and small oesophageal varices.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A randomised, double\u2010blind, placebo\u2010controlled study was conducted in 39 patients with cirrhosis and small oesophageal varices. Safety was based on frequency and severity of adverse events. Efficacy was determined by hepatic vein pressure gradient (<jats:styled-content style=\"fixed-case\">HVPG<\/jats:styled-content>) measured at baseline and day 84 following administration of <jats:styled-content style=\"fixed-case\">LAR<\/jats:styled-content> 10\u00a0mg (<jats:italic>n<\/jats:italic>\u00a0=\u00a015), 30\u00a0mg (<jats:italic>n<\/jats:italic>\u00a0=\u00a010) or saline (<jats:italic>n<\/jats:italic>\u00a0=\u00a014). Fasting and postprandial portal blood flow (<jats:styled-content style=\"fixed-case\">PBF<\/jats:styled-content>), superior mesenteric artery pulsatility index (<jats:styled-content style=\"fixed-case\">SMA<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">PI<\/jats:styled-content>), glucagon and octreotide levels were measured. An intention\u2010to\u2010treat analysis was performed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Four patients in the <jats:styled-content style=\"fixed-case\">LAR<\/jats:styled-content> 30 group (40%) withdrew from the study due to serious adverse events. No patient in the <jats:styled-content style=\"fixed-case\">LAR<\/jats:styled-content> 10 or control group had serious adverse events. There was no statistically significant decrease between <jats:styled-content style=\"fixed-case\">HVPG<\/jats:styled-content> at day 84 and baseline with <jats:styled-content style=\"fixed-case\">LAR<\/jats:styled-content> 30\u00a0mg (11.8\u00a0\u00b1\u00a02.3\u00a0mmHg vs. 14.1\u00a0\u00b1\u00a03.2), <jats:styled-content style=\"fixed-case\">LAR<\/jats:styled-content> 10\u00a0mg (15.3\u00a0\u00b1\u00a04.8\u00a0mmHg vs. 15.1\u00a0\u00b1\u00a03.8), or saline (13.3\u00a0\u00b1\u00a03.8\u00a0mmHg vs. 15.1\u00a0\u00b1\u00a04.3) (<jats:italic>P<\/jats:italic>\u00a0=\u00a00.26). Neither <jats:styled-content style=\"fixed-case\">PBF<\/jats:styled-content>,<jats:styled-content style=\"fixed-case\"> SMA<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">PI<\/jats:styled-content> nor plasma glucagon levels were significantly decreased from baseline (<jats:italic>P<\/jats:italic>\u00a0=\u00a00.56).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The absence of significant haemodynamic benefit, as well as the high frequency of severe adverse events associated with use of <jats:styled-content style=\"fixed-case\">LAR<\/jats:styled-content>, do not support the use of this agent in the treatment of portal hypertension.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1365-2036.2012.05050.x","type":"journal-article","created":{"date-parts":[[2012,3,3]],"date-time":"2012-03-03T11:59:13Z","timestamp":1330775953000},"page":"904-912","source":"Crossref","is-referenced-by-count":10,"title":["Randomised clinical trial: the safety and efficacy of long\u2010acting octreotide in patients with portal hypertension"],"prefix":"10.1111","volume":"35","author":[{"given":"N.","family":"Chandok","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology Mayo Clinic and Foundation Rochester MN USA"},{"name":"Division of Gastroenterology University of Western Ontario London ON Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. S.","family":"Kamath","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology Mayo Clinic and Foundation Rochester MN USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Blei","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology Northwestern Memorial Hospital Chicago IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Bosch","sequence":"additional","affiliation":[{"name":"Hepatic Hemodynamic Laboratory Hospital Clinic I Provincial and CIBERehd Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Carey","sequence":"additional","affiliation":[{"name":"Department of Hepatology Cleveland Clinic Cleveland OH USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Grace","sequence":"additional","affiliation":[{"name":"Gastroenterology Division Brigham and Women's Hospital, Harvard Medical School Boston MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. V.","family":"Kowdley","sequence":"additional","affiliation":[{"name":"Center for Liver Disease Digestive Disease Institute Virginia Mason Medical Center Seattle WA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Benner","sequence":"additional","affiliation":[{"name":"Section of Hepatology Division of Gastroenterology and Hepatology OHSU Portland OR USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. J.","family":"Groszmann","sequence":"additional","affiliation":[{"name":"Hepatic Hemodynamics Laboratory and, Section of Digestive Diseases Yale University School of Medicine West Haven CT USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,3]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21907"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gie.2005.07.031"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.46.suppl_3.iii1"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(94)80142-8"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840160513"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7119.1338"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2007.01262.x"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(97)80110-9"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199753040-00009"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(79)90330-5"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840210123"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840130417"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2001.20892"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2005.41381.x"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(97)80111-0"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.33469"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(97)80247-4"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510310304"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2012.05050.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2012.05050.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T10:25:36Z","timestamp":1698747936000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2012.05050.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":18,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["10.1111\/j.1365-2036.2012.05050.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2012.05050.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3]]}}}